JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
JOHNSON & JOHNSON
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
JOHNSON & JOHNSON revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $63.14B | $61.95B | $60.40B | $58.97B | $57.99B | $57.28B | $56.96B | $56.35B | $55.67B | $54.91B | $54.76B | $54.20B | 64.5% | +8.9% |
| MEDTECH | $34.79B | $34.41B | $33.79B | $33.18B | $32.64B | $32.06B | $31.86B | $31.34B | $30.91B | $30.74B | $30.40B | $29.50B | 35.5% | +6.6% |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. [Member] | $55.77B | $54.78B | $53.75B | $52.76B | $51.96B | $50.99B | $50.30B | $49.11B | $48.19B | $47.28B | $46.44B | $45.26B | 56.9% | +7.3% |
| International | $42.16B | $41.59B | $40.44B | $39.39B | $38.67B | $38.34B | $38.52B | $38.59B | $38.38B | $38.37B | $38.72B | $38.45B | 43.1% | +9.0% |
| Europe | $22.61B | $22.27B | $21.54B | $20.86B | $20.33B | $20.16B | $20.21B | $20.25B | $20.07B | $19.98B | $20.41B | $20.57B | 23.1% | +11.2% |
| Asia-Pacific, Africa | $14.45B | $14.31B | $14.03B | $13.79B | $13.65B | $13.50B | $13.59B | $13.59B | $13.57B | $13.72B | $13.76B | $13.47B | 14.8% | +5.8% |
| Western Hemisphere, excluding U.S. | $5.10B | $5.00B | $4.88B | $4.74B | $4.68B | $4.69B | $4.71B | $4.75B | $4.74B | $4.67B | $4.55B | $4.41B | 5.2% | +9.0% |
From the segment and revenue-disaggregation notes of Johnson & Johnson's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.